Logo

C4 Therapeutics and Merck KGaA Partner to Discover Protein Degraders Against Oncogenic Proteins

Share this
C4 Therapeutics

C4 Therapeutics and Merck KGaA Partner to Discover Protein Degraders Against Oncogenic Proteins

Shots:

  • C4 Therapeutics and Merck KGaA have signed a strategic license & collaboration agreement for the discovery of two targeted protein degraders against oncogenic proteins of interest from the former’s internal discovery pipeline
  • As per the agreement, C4T will obtain $16M upfront, ~$740M on achieving discovery, regulatory & commercial milestones plus mid-single to low-double-digit tiered future sales-based royalties for each product. C4T’s R&D costs will be covered by Merck KGaA
  • Furthermore, C4T’s Torpedo platform will be used for protein degraders’ discovery and Merck KGaA will handle the clinical development & commercialization of the discovered drug candidates

Ref: C4 Therapeutics | Image: C4 Therapeutics

Related News:- C4 Therapeutics Entered into an Exclusive License Agreement with Betta to Develop and Commercialize CFT8919 for Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions